Aiom
Anno II | Numero 9 | Gennaio 2017
Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
 
 
Notizie dalla ricerca
 
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Therapies targeting the mitogen-activated protein kinase signaling pathway can induce profound tumor regression in patients with advanced BRAF-mutated melanoma. Most patients develop resistance after several months of treatment, which is typically followed by rapid disease progression and death. BRAF- and mitogen-activated protein kinase kinase (MEK)-targeted therapies were initially thought to exert their therapeutic effects through direct inhibition of signaling within the tumor cell, resulting …
Continua a leggere
 
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of functionally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in various advanced cancers, particularly in melanoma. However, only a subset of cancer patients responds to current PD-L1/PD-1-blocking strategies, highlighting the need for further advancements in PD-L1/PD-1-based immunotherapy. Here, we report on a novel approach designed to combine PD-L1checkpoint inhibition with …
Continua a leggere
 
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab …
Continua a leggere
 
Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy
FDG-PET scans were performed on twenty seven patients with unresectable stage IIIC or IVmelanoma after prolonged treatment with anti-PD-1 antibodies to examine the hypothesis that patients with prolonged response to treatment may have metabolically inactive lesions by FDG-PET. Scans were performed at a median of 15.2 months (range 12-29 months) after starting treatment. Overall 15/27 (56%) patients had a positive FDG-PET scan. Eight patients with positive scans underwent …
Continua a leggere
 
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and radiotherapy (RT). We sought to review clinical outcomes of patients receiving RT and anti-PD-1 therapy. All patients receiving anti-PD-1 antibody and RT for metastatic melanoma were identified. RT and systemic treatment, clinical outcome, and toxicity data were collected. Fifty-three patients were included; 35 patients …
Continua a leggere
 
Appuntamenti AIOM
 
Aggiornamenti in oncologia: iponatriemia
Verona, 26 – 27 gennaio 2017
 
Studi clinici: metodologia
A good foundation
Negrar (VR), 8 – 9 marzo 2017
 
Studi clinici: criticità interpretative
Confidence, directness, relevance
Negrar (VR), 24 – 25 marzo 2017
 
La gestione del rischio in oncologia tra sicurezza e qualità
Conferenza Nazionale CIPOMO
Ascoli Piceno, 31 marzo – 1 aprile 2017
 
Questi e altri appuntamenti si possono consultare sul sito AIOM
www.aiom.it
 

 
Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di